NO20064754L - Kombinasjonsterapi - Google Patents
KombinasjonsterapiInfo
- Publication number
- NO20064754L NO20064754L NO20064754A NO20064754A NO20064754L NO 20064754 L NO20064754 L NO 20064754L NO 20064754 A NO20064754 A NO 20064754A NO 20064754 A NO20064754 A NO 20064754A NO 20064754 L NO20064754 L NO 20064754L
- Authority
- NO
- Norway
- Prior art keywords
- azd2171
- taxane
- human
- antiangiogenic
- warm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår en metode for fremkalling av en antiangiogen og/eller kar-permeabilitet-reduserende effekt hos et varmblodig dyr, så som et menneske, som eventuelt behandles med ioniserende stråling, spesielt en metode for behandling av kreft, spesielt kreft som omfatter en fast tumor, som omfatter administrering av AZD2171 i kombinasjon med et taksan; et farmasøytisk preparat som omfatter AZD2171 og et taksan; et kombinasjonsprodukt som omfatter AZD2171 og et taksan, for anvendelse i en metode for terapeutisk behandling av en menneske- eller dyrekropp; et sett som omfatter AZD2171 og et taksan; anvendelsen av AZD2171 og et taksan ved fremstilling av et medikament for anvendelse ved fremkalling av en antiangiogen og/eller kar-permeabilitet-reduserende effekt hos et varmblodig dyr, så som et menneske, som eventuelt behandles med ioniserende stråling.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0406445.7A GB0406445D0 (en) | 2004-03-23 | 2004-03-23 | Combination therapy |
PCT/GB2005/001089 WO2005092385A2 (en) | 2004-03-23 | 2005-03-22 | Combination therapy of azd2171 and a taxane |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064754L true NO20064754L (no) | 2006-10-20 |
Family
ID=32188481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064754A NO20064754L (no) | 2004-03-23 | 2006-10-20 | Kombinasjonsterapi |
Country Status (19)
Country | Link |
---|---|
US (1) | US20070135462A1 (no) |
EP (1) | EP1729807B1 (no) |
JP (1) | JP2007530520A (no) |
KR (1) | KR20070008651A (no) |
CN (1) | CN1997396A (no) |
AT (1) | ATE447973T1 (no) |
AU (1) | AU2005225197B2 (no) |
BR (1) | BRPI0508983A (no) |
CA (1) | CA2558598A1 (no) |
DE (1) | DE602005017590D1 (no) |
ES (1) | ES2335291T3 (no) |
GB (1) | GB0406445D0 (no) |
HK (1) | HK1096022A1 (no) |
IL (1) | IL177953A0 (no) |
MX (1) | MXPA06010757A (no) |
NO (1) | NO20064754L (no) |
NZ (1) | NZ549554A (no) |
WO (1) | WO2005092385A2 (no) |
ZA (1) | ZA200607554B (no) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
AU2005225192B2 (en) * | 2004-03-23 | 2008-10-09 | Astrazeneca Ab | Combination therapy |
NZ564189A (en) * | 2005-07-06 | 2011-04-29 | Astrazeneca Ab | Combination therapy of cancer with AZD2171 and gemcitabine |
NZ568812A (en) * | 2005-12-22 | 2011-09-30 | Astrazeneca Ab | Combination of AZD2171 and pemetrexed |
TW200922590A (en) * | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
JP3737518B2 (ja) * | 1996-03-12 | 2006-01-18 | ピージー−ティーエックスエル カンパニー, エル.ピー. | 水溶性パクリタキセルプロドラッグ |
US6596712B2 (en) * | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
CN1230123A (zh) * | 1996-07-11 | 1999-09-29 | 荷兰发马克有限公司 | 含碱性药物的酸加成盐的药物组合物 |
KR20080015482A (ko) * | 1999-02-10 | 2008-02-19 | 아스트라제네카 아베 | 혈관형성 억제제로서의 퀴나졸린 유도체 |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
EP1339458B1 (en) * | 2000-11-22 | 2007-08-15 | Novartis AG | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
KR101089462B1 (ko) * | 2002-11-04 | 2011-12-07 | 아스트라제네카 아베 | Src 티로신 키나제 억제제로서의 퀴나졸린 유도체 |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
GB0316123D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
AU2005225192B2 (en) * | 2004-03-23 | 2008-10-09 | Astrazeneca Ab | Combination therapy |
AU2005288736B2 (en) * | 2004-09-27 | 2008-08-14 | Astrazeneca Ab | Cancer combination therapy comprising AZD2171 and imatinib |
NZ564189A (en) * | 2005-07-06 | 2011-04-29 | Astrazeneca Ab | Combination therapy of cancer with AZD2171 and gemcitabine |
WO2007068895A1 (en) * | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
NZ568812A (en) * | 2005-12-22 | 2011-09-30 | Astrazeneca Ab | Combination of AZD2171 and pemetrexed |
-
2004
- 2004-03-23 GB GBGB0406445.7A patent/GB0406445D0/en not_active Ceased
-
2005
- 2005-03-22 CA CA002558598A patent/CA2558598A1/en not_active Abandoned
- 2005-03-22 US US10/594,234 patent/US20070135462A1/en not_active Abandoned
- 2005-03-22 CN CNA2005800092163A patent/CN1997396A/zh active Pending
- 2005-03-22 JP JP2007504471A patent/JP2007530520A/ja active Pending
- 2005-03-22 KR KR1020067021967A patent/KR20070008651A/ko not_active Application Discontinuation
- 2005-03-22 WO PCT/GB2005/001089 patent/WO2005092385A2/en active Application Filing
- 2005-03-22 EP EP05729377A patent/EP1729807B1/en active Active
- 2005-03-22 ES ES05729377T patent/ES2335291T3/es active Active
- 2005-03-22 AU AU2005225197A patent/AU2005225197B2/en not_active Ceased
- 2005-03-22 NZ NZ549554A patent/NZ549554A/en unknown
- 2005-03-22 AT AT05729377T patent/ATE447973T1/de not_active IP Right Cessation
- 2005-03-22 MX MXPA06010757A patent/MXPA06010757A/es active IP Right Grant
- 2005-03-22 DE DE602005017590T patent/DE602005017590D1/de active Active
- 2005-03-22 BR BRPI0508983-2A patent/BRPI0508983A/pt not_active IP Right Cessation
-
2006
- 2006-09-07 IL IL177953A patent/IL177953A0/en unknown
- 2006-09-08 ZA ZA200607554A patent/ZA200607554B/en unknown
- 2006-10-20 NO NO20064754A patent/NO20064754L/no not_active Application Discontinuation
-
2007
- 2007-03-20 HK HK07103004.1A patent/HK1096022A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2005092385A3 (en) | 2006-11-02 |
KR20070008651A (ko) | 2007-01-17 |
MXPA06010757A (es) | 2006-12-15 |
BRPI0508983A (pt) | 2007-08-28 |
DE602005017590D1 (de) | 2009-12-24 |
GB0406445D0 (en) | 2004-04-28 |
AU2005225197A1 (en) | 2005-10-06 |
IL177953A0 (en) | 2006-12-31 |
HK1096022A1 (en) | 2007-05-25 |
CA2558598A1 (en) | 2005-10-06 |
ZA200607554B (en) | 2008-05-28 |
JP2007530520A (ja) | 2007-11-01 |
EP1729807B1 (en) | 2009-11-11 |
AU2005225197B2 (en) | 2008-10-09 |
ATE447973T1 (de) | 2009-11-15 |
US20070135462A1 (en) | 2007-06-14 |
EP1729807A2 (en) | 2006-12-13 |
CN1997396A (zh) | 2007-07-11 |
ES2335291T3 (es) | 2010-03-24 |
NZ549554A (en) | 2009-12-24 |
WO2005092385A2 (en) | 2005-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
NO20064755L (no) | Kombinasjonsterapi | |
NO20056171L (no) | Kombinasjonsterapi | |
NO20064754L (no) | Kombinasjonsterapi | |
WO2005092384A3 (en) | Combination therapy with azd2171 and a platinum anti-tumour agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |